Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ViiV Healthcare Questions Natco's Ability To Make And Sell Selzentry In India; Stays Silent On Voluntary License Issue

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - ViiV Healthcare - formed by GlaxoSmithKline Pharmaceuticals Plc and Pfizer Inc. in 2009 to work on a range of HIV/AIDS medications - struck back with a volley of questions to Natco Pharma Ltd., which had sought a voluntary license in December 2010 to manufacture generic versions of Selzentry

You may also be interested in...



Merck And Cipla Bury Differences To Co-market Raltegravir In India

Merck agreed to co-market its patented HIV product raltegravir in India with rival Cipla, bringing to end what had started as an attempt for a voluntary license and could have veered toward a compulsory license.

ViiV May Dodge Compulsory License For Celsentri In India; Commits To Competitive Price Via Local Ally

Unfazed by the recent compulsory license granted to Natco for Bayer’s Nexavar, ViiV closes in on a local partnership.

ViiV May Dodge Compulsory License For Celsentri In India; Commits To Competitive Price Via Local Ally

Unfazed by the recent compulsory license granted to Natco for Bayer’s Nexavar, ViiV closes in on a local partnership.

Related Content

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel